



06-14-04

1642
Jfu
71

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission:	8 pages plus 64 references	Application No.	09/454,481
		Filing Date	December 3, 1999
		First Named Inventor	James ALLISON
		Examiner Name	S.L. Rawlings
		Group Art Unit	1642

Total Number of Pages in This Submission:	8 pages plus 64 references	Attorney Docket No.	A-68668
---	-------------------------------	---------------------	---------

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment & Recordation Cover Sheet (in duplicate)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Deposit Account Authorization 50-2319	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> 64 cited references
<input checked="" type="checkbox"/> Information Disclosure Statement & PTO-1449 – 8 pages	<input type="checkbox"/> Request for Refund	<input checked="" type="checkbox"/> Return Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, No. of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Todd A. Lorenz, Reg. No. 39,754 DORSEY & WHITNEY LLP 4 Embarcadero Center, Suite 3400 San Francisco, CA 94111 Telephone : 415 781 1989	Customer Number 32940
Signature	Euk Y. Oh, Reg. No. 54,345 for Todd A. Lorenz	
Date	June 10, 2004	

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "EXPRESS MAIL POST OFFICE TO ADDRESSEE," Express Mail No. EV 424741793 US, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

6/10/04

Typed or printed name	Brent Yonehara
Signature	
	Date June 10, 2004



PATENT
Docket No.: A-68668/RFT/TAL/CYO
File No.: 465174-00312

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ALLISON et al.

Serial No.: 09/454,481

Filing Date: December 3, 1999

For: STIMULATION OF T CELLS
AGAINST SELF ANTIGENS
USING CTLA-4 BLOCKING
AGENTS

Examiner: Rawlings, S.L.

Art Unit: 1642

Confirmation No. 3796

EXPRESS MAILING CERTIFICATE

Express Mail Label No.: EV 424741793 US

Date of Deposit: JUNE 10, 2004

I hereby state that this paper, including any listed enclosures, and/or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signed: 

Brent Yonehara

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying substitute form for form PTO/SB/8A. Copies of references are provided, except for those references marked with an asterisk (*). These marked references were disclosed with Applicants' responses to the office actions dated November 23, 2001 and December 8, 2003. Therefore, no copies of these references are provided.

Serial No. 09/454,481
Filing Date: December 3, 1999

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed before the mailing of a first office action on the merits following a Request for Continued Examination under 37 C.F.R. § 1.114, and therefore no fee is required.

While no fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any required fees, or credit any overpayment to Dorsey & Whitney LLP Deposit Account No. 50-2319 (Our Order No. A-68668 (465174-00312)).

Dated: June 10, 2004

BY:

Respectfully submitted,
DORSEY & WHITNEY LLP



Euk Y. Oh, Reg. No. 54,345 for
Todd A. Lorenz, Reg. No. 39,754
Filed Under 37 C.F.R. § 1.34(a)

Customer Number: 32940
Dorsey & Whitney LLP
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/454,481
				Filing Date	December 3, 1999
				First Named Inventor	ALLISON, James P.
				Art Unit	1642
				Examiner Name	Rawlings, S.L.
Sheet	1	of	5	Attorney Docket Number	
A-68668/RFT/TAL/CYO (465174-00312)					

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	5,434,131	07-18-1995	Linsley et al.		
A2	5,770,197	06-23-1998	Linsley et al.		
A3	5,773,253	06-30-1998	Linsley et al.		
A4	5,844,095	12-01-1998	Linsley et al.		
A5	5,851,795	12-22-1998	Linsley et al.		
A6	5,869,057	02-09-1999	Rock		
A7	5,885,796	03-23-1999	Linsley et al.		
A8	5,968,510	10-19-1999	Linsley et al.		
A9	5,977,318	11-02-1999	Linsley et al.		
A10	6,090,914	07-18-2000	Linsley et al.		
A11	6,323,027 B1	11-27-2001	Burkly et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
✓ B1	WO 95/01994 A1	01-19-1995	Synergen, Inc.			
✓ B2	WO 95/34320 A2	12-22-1995	Regents of the University of Minnesota			
✓ B3	WO 96/14865 A1	05-23-1996	Repligen Corp.			
✓ B4	WO 00/32231 A1	06-08-2000	The Regents of the University of California			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	ALLISON, J.P., et al., "The yin and yang of T cell co-stimulation," <i>Science</i> 270(5238):932-933 (Nov. 1995).	
	C2	BELLDEGRUN, A., et al., "Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity," <i>Cancer Res.</i> Jan. 1988, 48:206-214.	
	C3	BLUESTONE, J.A., "New perspectives of CD28-B7-mediated T cell costimulation," <i>Immunity</i> 2(6):555-559 (Jun. 1995).	
	C4	BRUNET, J.-F., et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> 328(6127):267-270 (Jul. 1987).	
	C5 *	CHAUDHARY, J., et al., "Caloxin: a novel plasma membrane Ca ²⁺ pump inhibitor," <i>Am. J. Physiol. Cell Physiol.</i> 280(4):C1027-C1030 (Apr. 2001).	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



JUN 10 2004

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	2	of	5	Application Number	09/454,481
				Filing Date	December 3, 1999
				First Named Inventor	ALLISON, James P.
				Art Unit	1642
				Examiner Name	Rawlings, S.L.
				Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C6	CHEN, L., et al., "Costimulation of antitumor activity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4," <i>Cell</i> 71(7):1093-1102 (Dec. 1992).	
	C7	DAMLE, N., et al., "Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7," <i>J. Immunol.</i> 152(6):2686-2697 (Mar. 1994).	
	C8	DARIAVACH, P., et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> 18(12):1901-1905 (Dec. 1988).	
	C9	DE WAAL MALEYFT, R., et al., "CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 23(2):418-424 (Feb. 1993).	
	C10	DEVITA, V., "The relationship between tumor mass and resistance to chemotherapy," <i>Cancer</i> 51(7):1209-1220 (Apr. 1983).	
	C11 *	DEVLIN, J., et al., "Random peptide libraries: a source of specific protein binding molecules," <i>Science</i> 249(4967):404-406 (Jul. 1990).	
	C12	FREEMAN, G.J., et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," <i>Science</i> 262(5135):907-909 (Nov. 1993).	
	C13 *	GOODSON, R., et al., "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," <i>Proc. Natl. Acad. Sci. USA</i> 91(15):7129-7133 (Jul. 1994).	
	C14 *	GRIBBEN, J., et al., "CTLA4 mediates antigen-specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci. USA</i> 92(3):811-815 (Jan. 1995).	
	C15	GROSS, J., et al., "Identification and distribution of the costimulatory receptor CD28 in the mouse," <i>J. Immunol.</i> 149(2):380-388 (Jul. 1992).	
	C16	GROSS, J., et al., "The murine homologue of the T lymphocyte antigen CD28," <i>J. Immunol.</i> 144(8):3201-3210 (Apr. 1990).	
	C17	HARDING, F., et al., "CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help," <i>J. Exp. Med.</i> 177(6):1791-1796 (Jun. 1993).	
	C18	HARDING, F., et al., "CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> 356(6370):607-609 (Apr. 1992).	
	C19	HARPER, K., et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J. Immunol.</i> 147(5):1037-1044 (Aug. 1991).	
	C20 *	HODI, J.S., et al., "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients," <i>Proc. Natl. Acad. Sci. USA</i> 100(8):4712-4717 (Apr. 2003).	
	C21	HUANG, Y.W., et al., "Immunotherapy of multiple myeloma," <i>Stem Cells</i> 13(2):123-134 (Mar. 1995).	
	C22	JENKINS, M., et al., "T-cell unresponsiveness <i>in vivo</i> and <i>in vitro</i> : fine specificity induction and molecular characterization of the unresponsive state," <i>Immunol. Rev.</i> 95():113-135 (Feb. 1987).	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified)				Complete if Known	
				Application Number	09/454,481
				Filing Date	December 3, 1999
				First Named Inventor	ALLISON, James P.
				Art Unit	1642
				Examiner Name	Rawlings, S.L.
Sheet	3	of	5	Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	C23	JENKINS, M.K., "The ups and downs of T cell activation," <i>Immunity</i> 1(6):444-446 (Sep. 1994).		
	C24	JUNE, C.H., et al., "The B7 and CD28 receptor families," <i>Immunol. Today</i> 15(7):321-331 (Jul. 1994).		
	C25	JUNE, C.H., et al., "Role of the CD28 receptor in T-cell activation," <i>Immunol. Today</i> 11(6):211-216 (Jun. 1990).		
	C26	KRUMMEL, M., et al., "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J. Exp. Med.</i> 182(2):459-465 (Aug. 1995).		
	C27	KWON, E., et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc. Natl. Acad. Sci. USA</i> 94(15):8099-8103 (Jul. 1997).		
	C28	LANE, P., et al., "Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human γ1," <i>Immunology</i> 80(1):56-61 (Sep. 1993).		
	C29	LENSCHOW, D.J., et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc. Natl. Acad. Sci. USA</i> 90(23):11054-11058 (Dec. 1993).		
	C30	LENSCHOW, D.J., et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig," <i>Science</i> 257(5071):789-792 (Aug. 1992).		
	C31	LIN, H., et al., "Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion," <i>J. Exp. Med.</i> 178(5):1801-1806 (Nov. 1993).		
	C32	LINDSTEN, T., et al., "Characterization of CTLA-4 structure and expression on human cells," <i>J. Immunol.</i> 151(7):3489-3499 (Oct. 1993).		
	C33	LINSLEY, P., et al., "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," <i>J. Exp. Med.</i> 176(6):1595-1604 (Dec. 1992).		
	C34	LINSLEY, P., et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> 174(3):561-569 (Sep. 1991).		
	C35	LINSLEY, P., et al., "Distinct roles for CD28 and cytotoxic lymphocyte-associated molecule-4 receptors during T cell activation," <i>J. Exp. Med.</i> 182(2):282-285 (Aug. 1995).		
	C36	LINSLEY, P., et al., "Immunosuppressive in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> 257(5071):792-795 (Aug. 1992).		
	C37	LINSLEY, P., et al., "Lymphocyte activation: T-cell regulation by CTLA-4," <i>Curr. Biol.</i> 6(4):398-400 (Apr. 1996).		
	C38	LINSLEY, P., et al., "The role of the CD28 receptor during T cell responses to antigen," <i>Annu. Rev. Immunol.</i> 11():191-212 (1993).		
	C39	NELSON, A.J., et al., "Medullary thymic epithelium expresses a ligand for CTLA4 in situ and in vitro," <i>J. Immunol.</i> 151(5):2453-2461 (Sep. 1993).		
	C40 *	OLDENBURG, K., et al., "Peptide ligands for a sugar-binding protein isolated from a random peptide library," <i>Proc. Natl. Acad. Sci. USA</i> 89(12):5393-5397 (Jun. 1992).		
	C41	PEACH, R., et al., "Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1," <i>J. Exp. Med.</i> 180(6):2049-2058 (Dec. 1994).		


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

 Substitute for form 1449A/PTO (Modified)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number 09/454,481	
Sheet	4	of	5	Filing Date December 3, 1999	
				First Named Inventor ALLISON, James P.	
				Art Unit 1642	
				Examiner Name Rawlings, S.L.	
				Attorney Docket Number A-68668/RFT/TAL/CYO (465174-00312)	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ⁶
	C42 *	PHAN, G.Q., et al. "Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma," <i>Proc. Natl. Acad. Sci. USA</i> 100(14):8372-8377 (Jul. 2003).	
	C43	ROSENBERG, S., et al., "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone," <i>New Engl. J. Med.</i> 316(15):891-897 (Apr. 1987).	
	C44	ROSENTHAL, F., et al., "Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity," <i>Curr. Opin. Oncol.</i> 6(6):611-615 (Nov. 1994).	
	C45	SCHWARTZ, R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> 71(7):1065-1068 (Dec. 1992).	
	C46 *	SPARKS, A., et al., "Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries," <i>J. Biol. Chem.</i> 269(39):23853-23856 (Sep. 1994).	
	C47	TJOA, B., et al., "Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection," <i>Cancer Res.</i> 54(1):204-208 (Jan. 1994).	
	C48	TOWNSEND, S., et al., "Specificity and longevity of antitumor immune responses induced by B7-transfected tumors," <i>Cancer Res.</i> 54(24):6477-6483 (Dec. 1994).	
	C49	TRAVIS, J., "A stimulating new approach to cancer treatment," <i>Science</i> 259(5093):310-311 (Jan. 1993).	
	C50	TURKA, L., et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 89(22):11102-11105 (Nov. 1992).	
	C51	VAN ELSAS, A., et al., "Blockade of CTLA-4 cinnubed wutg a GM-CSF vaccine cures mice from the highly tumorigenic, poorly immunogenic melanoma B16-BL6, and induces depigmentation," <i>FASEB J.</i> 12(5):A908 (Mar. 1998) (Abstract #5258).	
	C52	VAN ELSAS, A., et al., "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation," <i>J. Exp. Med.</i> 190(3):355-366 (Aug. 1999).	
	C53	VAN SEVENTER, G., et al., "Roles of multiple accessory molecules in T-cell activation," <i>Curr. Opin. Immunol.</i> 3(3):294-303 (Jun. 1991).	
	C54	WATERHOUSE, P., et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> 270(5238):985-988 (Nov. 1995).	
	C55	WELLS, A., et al., "Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy," <i>J. Clin. Invest.</i> 108(6):895-903 (Sep. 2001).	
	C56	WOODLE, E.S., et al., "In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells," <i>Transplantation</i> 61(5):798-803 (Mar. 1996).	
	C57	WU, Y., et al., "CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion," <i>J. Exp. Med.</i> 185(7):1327-1335 (Apr. 1997).	
	C58 *	XU, H., et al., "A novel PCNA-binding motif identified by the panning of a random peptide display library," <i>Biochemistry</i> 40(14):4512-4520 (Apr. 2001).	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial-number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	5	of	5	Application Number	09/454,481
				Filing Date	December 3, 1999
				First Named Inventor	ALLISON, James P.
				Art Unit	1642
				Examiner Name	Rawlings, S.L.
				Attorney Docket Number	
				A-68668/RFT/TAL/CYO (465174-00312)	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
C59 *	YANOFSKY, S., et al., "High affinity type I interleukin 1 receptor antagonists discovered by screenin grecombinant peptide libraries," <i>Proc. Natl. Acad. Sci. USA</i> 93(14):7381-7386 (Jul. 1996).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2